一種新型樣本制備平臺(tái)能夠?yàn)楹怂岱蛛x、定量、標(biāo)準(zhǔn)化和下游分析準(zhǔn)備提供新的解決方案。

這種平臺(tái)叫做Vidiera NsP，是以Beckman Coulter公司(Fullerton, CA, USA)的Biomek自動(dòng)化和診斷試管處理工藝為基礎(chǔ)的，專(zhuān)門(mén)設(shè)計(jì)用于滿足醫(yī)院和參考實(shí)驗(yàn)室對(duì)分子學(xué)檢測(cè)不斷增長(zhǎng)的需求。

Vidiera可以用于病毒學(xué)和病理學(xué)的分子學(xué)診斷，還可以整合進(jìn)Beckman Coulter的Vidiera NsD核酸樣本檢測(cè)系統(tǒng)。Vidiera NsP能夠被用于制備分子診斷實(shí)驗(yàn)室目前進(jìn)行的絕大多數(shù)下游分析設(shè)備，而Vidiera NsD能夠允許在一間房間內(nèi)把分析前檢測(cè)功能進(jìn)行集中。Vidiera NsP將會(huì)向高度復(fù)雜的診斷實(shí)驗(yàn)室推廣。

“我們公司的新型Vidiera系列產(chǎn)品，將我們的專(zhuān)業(yè)特長(zhǎng)應(yīng)用于臨床診斷和科研實(shí)驗(yàn)室自動(dòng)化，有利于不斷增長(zhǎng)的分子學(xué)檢測(cè)方法?！盉ruce Wallace如此解釋說(shuō)，他是Beckman Coulter公司核酸檢測(cè)部門(mén)的副總裁。“這條產(chǎn)品線是我們生物醫(yī)學(xué)檢測(cè)持續(xù)發(fā)展戰(zhàn)略的一個(gè)明確范例，證明了我們雄厚的專(zhuān)業(yè)優(yōu)勢(shì)將會(huì)為診斷實(shí)驗(yàn)室?guī)?lái)全新的解決方案?！?

Beckman Coulter在全球范圍內(nèi)已經(jīng)安裝了超過(guò)200,000套系統(tǒng)，把生物醫(yī)學(xué)檢測(cè)范圍從尖端醫(yī)學(xué)科研和臨床實(shí)驗(yàn)室擴(kuò)大至實(shí)驗(yàn)室診斷和床邊檢測(cè)。

Sample Preparation for Molecular Diagnostics
 
A new sample preparation platform represents a new solution for nucleic acid isolation, quantification, normalization, and reaction set-up for downstream assay analysis.

Called Vidiera NsP, the platform is based on the Biomek automation and diagnostic primary tube-handling technologies of Beckman Coulter (Fullerton, CA, USA) and is specifically designed to meet the growing need for molecular testing in hospital and reference laboratories.

Vidiera can be used for molecular diagnostic applications in virology and pathology and can be integrated with Beckman Coulter’s Vidiera NsD nucleic sample detection system. Vidiera NsP can be used for setting-up reactions for most major downstream analytical instruments that molecular diagnostic laboratories have today, while Vidiera NsD enables labs to centralize pre-analytic functions in one room and to streamline the process. Vidiera NsP will be marketed to high-complexity diagnostic laboratories.

“Our new Vidiera products bring together our expertise in clinical diagnostics and research laboratory automation to benefit the growing field of molecular testing,” explained Bruce Wallace, vice president, nucleic acid testing business, Beckman Coulter.
“This product line is a clear example of our biomedical testing continuum strategy and demonstrates the advantage our broad range of expertise gives us in bringing new solutions to the diagnostic workplace.”

Beckman Coulter has more than 200,000 installed systems around the world that span the biomedical testing continuum from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing.